Mohammad Reza Vakili
Overview
Explore the profile of Mohammad Reza Vakili including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
274
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sadat S, Vakili M, Abd-El Hafeez S, Paladino M, Hall D, Weinfeld M, et al.
Mol Pharm
. 2024 May;
21(7):3240-3255.
PMID: 38785196
Inhibitors of a DNA repair enzyme known as polynucleotide kinase 3'-phosphatase (PNKP) are expected to show synergistic cytotoxicity in combination with topoisomerase I (TOP1) inhibitors in cancer. In this study,...
2.
Mahmoodi Y, Mehrnejad F, Khanmohammadi S, Shahriari M, Rahimi F, Vakili M, et al.
Int J Biol Macromol
. 2022 May;
213:83-95.
PMID: 35598725
In the present research, we performed a combination of detailed computational and spectroscopic methods to determine the effect of crystalline nanocellulose (CNC) on the structure and dynamics of human lysozyme...
3.
Paiva I, Vakili M, Soleimani A, Tabatabaei Dakhili S, Munira S, Paladino M, et al.
Mol Pharm
. 2022 Mar;
19(6):1825-1838.
PMID: 35271294
The disruption of polynucleotide kinase/phosphatase (PNKP) in colorectal cancer (CRC) cells deficient in phosphatase and tensin homolog (PTEN) is expected to lead to the loss of cell viability by a...
4.
Vakili M, Mohammed-Saeid W, Aljasser A, Hopwood-Raja J, Ahvazi B, Hrynets Y, et al.
Carbohydr Polym
. 2021 Jan;
255:117332.
PMID: 33436175
To fabricate a mucoadhesive hydrogel with superior properties for local delivery of cisplatin (CDDP) to colorectal cancer, a hardcore bottle-brush polymer (HCBBP) was developed through grafting of poly(acrylic acid) (PAA)...
5.
Sadat S, Vakili M, Paiva I, Weinfeld M, Lavasanifar A
Pharmaceutics
. 2020 Nov;
12(11).
PMID: 33138058
The clinical use of 7-ethyl-10-hydroxy-camptothecin (SN-38), which is the active metabolite of irinotecan, has been hampered because of its practical water-insolubility. In this study, we successfully synthesized two self-associating SN-38-polymer...
6.
Paiva I, Mattingly S, Wuest M, Leier S, Vakili M, Weinfeld M, et al.
Mol Pharm
. 2020 Apr;
17(5):1470-1481.
PMID: 32233491
Polymeric micellar nanoparticles represent versatile and biocompatible platforms for targeted drug delivery. However, tracking their biodistribution, stability, and clearance profile in vivo is challenging. The goal of this study was...
7.
Al-Lawati H, Vakili M, Lavasanifar A, Ahmed S, Jamali F
Mol Pharm
. 2020 Feb;
17(4):1377-1386.
PMID: 32023064
In this study, we tested whether the extent of drug presence in the heart contributes to the elevated cardiovascular risk of nonsteroidal anti-inflammatory drugs (NSAIDs). A fluorescently tagged nanoformulation of...
8.
Saqr A, Vakili M, Huang Y, Lai R, Lavasanifar A
ACS Omega
. 2019 Nov;
4(20):18867-18879.
PMID: 31737848
The objective of this work was to develop rituximab (RTX)-modified polymeric micelles for targeting of B-cell lymphoma cells, through postinsertion of RTX-poly(ethylene glycol)-1,2-distearoyl--glycero-3-phosphoethanolamine (RTX-PEG-DSPE) into methoxy poly(ethylene oxide)-poly(ε-caprolactone) (PEO-PCL) or...
9.
Alshamsan A, Kalam M, Vakili M, Binkhathlan Z, Raish M, Ali R, et al.
Int J Pharm
. 2019 Jul;
569:118573.
PMID: 31356955
The main objective of this study was to investigate the potential of poly(α-carboxylate-co-α-benzylcarboxylate-ε-caprolactone)-block-poly(ethylene glycol)-block-poly(α-carboxylate-co-α-benzylcarboxylate-ε-caprolactone) (PCBCL-b-PEG-b-PCBCL; denoted as PolyGel™) as an in situ gel system for ocular delivery of CyA. The...
10.
Huang Y, Vakili M, Molavi O, Morrissey Y, Wu C, Paiva I, et al.
Cancers (Basel)
. 2019 Feb;
11(2).
PMID: 30791634
STAT3 is an oncoprotein which has been shown to contribute to drug resistance in multiple myeloma (MM). Nonetheless, the clinical utility of STAT3 inhibitors in treating MM has been limited,...